Journal article

Absence of pro-survival A1 has no impact on inflammatory cell survival in vivo during acute lung inflammation and peritonitis

Lahiru Gangoda, Robyn L Schenk, Sarah A Best, Christina Nedeva, Cynthia Louis, Damian B D'Silva, Kirsten Fairfax, Andrew G Jarnicki, Hamsa Puthalakath, Kate D Sutherland, Andreas Strasser, Marco J Herold

CELL DEATH AND DIFFERENTIATION | SPRINGERNATURE | Published : 2021

Abstract

Inflammation is a natural defence mechanism of the body to protect against pathogens. It is induced by immune cells, such as macrophages and neutrophils, which are rapidly recruited to the site of infection, mediating host defence. The processes for eliminating inflammatory cells after pathogen clearance are critical in preventing sustained inflammation, which can instigate diverse pathologies. During chronic inflammation, the excessive and uncontrollable activity of the immune system can cause extensive tissue damage. New therapies aimed at preventing this over-activity of the immune system could have major clinical benefits. Here, we investigated the role of the pro-survival Bcl-2 family m..

View full abstract

Grants

Awarded by Australian National Health and Medical Research Council (NHMRC)


Awarded by Leukaemia and Lymphoma Society of America


Awarded by Cancer Council of Victoria


Awarded by Leukaemia and Lymphoma Society


Awarded by CASS Foundation Science and Medicine


Funding Acknowledgements

This work was supported by grants and fellowships from the Australian National Health and Medical Research Council (NHMRC) (Project Grants 1186575, 1159658 and 1145728 to MJH, 1143105 to MJH and AS), Programme Grant 1016701 to AS and Fellowships 1020363 to AS, 1156095 to MJH, the Leukaemia and Lymphoma Society of America (LLS SCOR 7015-18 to AS and MJH), the Cancer Council of Victoria (project grant 1147328 to MJH, 1052309 to AS and Venture Grant to MJH and AS), the Australian Phenomics Network (to MJH), the Leukaemia and Lymphoma Society Grant #7001-13 to AS; the estate of Anthony (Toni) Redstone OAM and The Craig Perkins Cancer Research Foundation; and operational infrastructure grants through the Australian Government NHMRCS IRIISS and the Victorian State Government Operational Infrastructure Support to AS and the CASS Foundation Science and Medicine Grant #9393 to LG. KF is the recipient of the Alex Gadomski Fellowship, funded by Maddie Riewoldt's Vision. KDS is supported by the Peter and Julie Alston Centenary Fellowship.